MX2010004726A - Antigeno asociado con artritis reumatoide. - Google Patents

Antigeno asociado con artritis reumatoide.

Info

Publication number
MX2010004726A
MX2010004726A MX2010004726A MX2010004726A MX2010004726A MX 2010004726 A MX2010004726 A MX 2010004726A MX 2010004726 A MX2010004726 A MX 2010004726A MX 2010004726 A MX2010004726 A MX 2010004726A MX 2010004726 A MX2010004726 A MX 2010004726A
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
antigen associated
isoform
fibronectin
binds
Prior art date
Application number
MX2010004726A
Other languages
English (en)
Inventor
Manuela Kaspar
Eveline Trachsel
Kathrin Schwager
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of MX2010004726A publication Critical patent/MX2010004726A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un miembro de enlace que une la isoforma del Extra Dominio-A (ED-A) de fibronectina para la detección y el tratamiento de artritis reumatoide.
MX2010004726A 2007-10-30 2008-10-27 Antigeno asociado con artritis reumatoide. MX2010004726A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98360607P 2007-10-30 2007-10-30
PCT/EP2008/009070 WO2009056268A1 (en) 2007-10-30 2008-10-27 An antigen associated with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MX2010004726A true MX2010004726A (es) 2010-05-20

Family

ID=40282320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004726A MX2010004726A (es) 2007-10-30 2008-10-27 Antigeno asociado con artritis reumatoide.

Country Status (18)

Country Link
US (4) US8222377B2 (es)
EP (3) EP3281952B1 (es)
JP (3) JP5106635B2 (es)
KR (3) KR101608544B1 (es)
CN (2) CN103396483B (es)
AU (1) AU2008317941B2 (es)
BR (1) BRPI0818272B8 (es)
CA (1) CA2704296C (es)
DK (2) DK2209805T3 (es)
ES (2) ES2807753T3 (es)
HU (2) HUE050038T2 (es)
MX (1) MX2010004726A (es)
NO (1) NO2209805T3 (es)
PL (2) PL2209805T3 (es)
PT (2) PT3281952T (es)
RU (2) RU2486198C2 (es)
SI (2) SI2209805T1 (es)
WO (1) WO2009056268A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070084556A1 (en) 2005-10-14 2007-04-19 Langseder Neal E Method of applying a label to a squeeze tube
EA018985B1 (ru) * 2007-04-02 2013-12-30 Филоджен С.П.А. Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
KR101608544B1 (ko) 2007-10-30 2016-04-01 필로겐 에스.피.에이. 류마티스 관절염과 연관된 항원
WO2010078950A2 (en) 2009-01-07 2010-07-15 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
WO2011015333A2 (en) 2009-08-05 2011-02-10 Philogen S.P.A. Targeting of bone marrow neovasculature
WO2013014149A1 (en) * 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate
EA201500208A1 (ru) * 2012-08-08 2015-07-30 Роше Гликарт Аг Слитые белки, содержащие интерлейкин-10, и их применения
TWI499426B (zh) * 2012-09-27 2015-09-11 Philogen Spa 與發炎性腸病有關之抗原
CN111329994A (zh) * 2012-10-03 2020-06-26 菲罗根股份公司 与炎性肠病有关的抗原
RU2016135788A (ru) * 2014-02-06 2018-03-07 Ф.Хоффманн-Ля Рош Аг Иммуноконъюгаты интерлейкина 10
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
PE20180797A1 (es) 2015-07-16 2018-05-09 Philogen Spa Inmunoconjugados de il22
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
JP2017197558A (ja) * 2017-06-07 2017-11-02 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
CA3065153C (en) 2017-06-07 2023-09-05 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
AU2020459746A1 (en) 2020-07-20 2023-03-16 Deka Biosciences, Inc. Dual cytokine fusion proteins comprising IL-10
WO2022018126A1 (en) 2020-07-22 2022-01-27 Philogen S.P.A. Treatment of pulmonary hypertension
CN113480636B (zh) * 2021-06-23 2023-11-03 烟台科瑞斯生物技术有限责任公司 重组人纤连蛋白及其制备、活性测定和稳定性实验方法
WO2023175077A1 (en) 2022-03-17 2023-09-21 Philogen S.P.A Anti-ed-a antibodies for the treatment of pulmonary hypertension

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
EP0580859A4 (en) 1991-03-26 1994-09-14 Otsuka Pharma Co Ltd Anti-eda monoclonal antibody
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
AU6098994A (en) 1993-01-27 1994-08-15 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
ES2269361T3 (es) 2000-02-24 2007-04-01 Philogen S.P.A. Composiciones y metodos para tratamiento de la angiogenesis en lesiones patologicas.
AU2001246850A1 (en) * 2000-04-06 2001-10-23 Kyowa Hakko Kogyo Co. Ltd. Diagnostics and remedies for rheumatoid arthritis
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
KR20030045056A (ko) * 2000-09-07 2003-06-09 쉐링 악티엔게젤샤프트 ＥＤｂ-피브로넥틴 도메인의 수용체
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
WO2004000216A2 (en) 2002-06-21 2003-12-31 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
CA2501616C (en) * 2002-10-08 2015-05-12 Immunomedics, Inc. Antibody therapy
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
WO2004094612A2 (en) 2003-04-22 2004-11-04 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
CA2533878A1 (en) 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US20060024722A1 (en) 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ATE432293T1 (de) 2004-11-09 2009-06-15 Philogen Spa Antikörper gegen tenascin-c
EP1831254B1 (en) * 2004-12-23 2012-06-06 Molmed SpA Conjugation product
EP1891102B1 (en) * 2005-05-11 2010-03-03 Philogen S.p.A. Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
CA2612186A1 (en) 2005-06-23 2007-01-04 Emory University Imaging agents
EP2015775B1 (en) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
MX2008013575A (es) * 2006-05-08 2008-11-04 Philogen Spa Citoquinas dirigidas a anticuerpos para terapia.
EA018985B1 (ru) * 2007-04-02 2013-12-30 Филоджен С.П.А. Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
EP2612869B1 (en) * 2007-07-25 2015-01-14 Philogen S.p.A. Ed-a antigen of fibrinogen that is associated with lymphomas
KR101608544B1 (ko) 2007-10-30 2016-04-01 필로겐 에스.피.에이. 류마티스 관절염과 연관된 항원
WO2010078950A2 (en) 2009-01-07 2010-07-15 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
EP2379117A2 (en) 2009-01-07 2011-10-26 Philogen S.p.A. Cancer treatment
CA2811667C (en) 2010-09-29 2017-09-05 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
WO2013014149A1 (en) 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate
CN111329994A (zh) 2012-10-03 2020-06-26 菲罗根股份公司 与炎性肠病有关的抗原
EP2988784A1 (en) 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
AU2014257906A1 (en) 2013-04-26 2015-12-10 Philogen S.P.A. IL4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
DK3281952T3 (da) 2020-08-03
SI2209805T1 (sl) 2017-11-30
EP2209805B1 (en) 2017-09-06
KR20100101587A (ko) 2010-09-17
US9556257B2 (en) 2017-01-31
CN101918443B (zh) 2013-07-17
KR101836968B1 (ko) 2018-03-12
ES2807753T3 (es) 2021-02-24
US10385121B2 (en) 2019-08-20
CA2704296C (en) 2017-08-22
CN101918443A (zh) 2010-12-15
KR20160039305A (ko) 2016-04-08
PT3281952T (pt) 2020-07-23
WO2009056268A1 (en) 2009-05-07
HUE037036T2 (hu) 2018-08-28
JP5106635B2 (ja) 2012-12-26
EP3783019A1 (en) 2021-02-24
BRPI0818272B1 (pt) 2021-01-12
KR101608544B1 (ko) 2016-04-01
HUE050038T2 (hu) 2020-11-30
PL2209805T3 (pl) 2018-01-31
DK2209805T3 (en) 2017-10-16
US20100260707A1 (en) 2010-10-14
JP2011502137A (ja) 2011-01-20
PL3281952T3 (pl) 2020-11-16
CN103396483B (zh) 2016-11-23
EP2209805A1 (en) 2010-07-28
EP3281952B1 (en) 2020-06-24
NO2209805T3 (es) 2018-02-03
EP3281952A1 (en) 2018-02-14
BRPI0818272A2 (pt) 2015-04-14
US20170298122A1 (en) 2017-10-19
JP6198703B2 (ja) 2017-09-20
JP2013040183A (ja) 2013-02-28
CA2704296A1 (en) 2009-05-07
JP2015091799A (ja) 2015-05-14
CN103396483A (zh) 2013-11-20
RU2013115891A (ru) 2014-10-20
JP6154594B2 (ja) 2017-06-28
ES2646228T3 (es) 2017-12-12
AU2008317941B2 (en) 2015-01-22
US20190352384A1 (en) 2019-11-21
KR102002739B1 (ko) 2019-07-23
BRPI0818272B8 (pt) 2021-05-25
RU2649368C2 (ru) 2018-04-02
RU2486198C2 (ru) 2013-06-27
RU2010121874A (ru) 2011-12-10
KR20180027640A (ko) 2018-03-14
SI3281952T1 (sl) 2020-09-30
PT2209805T (pt) 2017-11-14
US8222377B2 (en) 2012-07-17
US20120244114A1 (en) 2012-09-27
AU2008317941A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
MX2010004726A (es) Antigeno asociado con artritis reumatoide.
MX2009010639A (es) Nuevo antigeno asociado con la neovasculatura de metastasis tumoral.
EA201070179A1 (ru) Антиген, связанный с вариантами рака легкого и лимфомами
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
IL256728A (en) Systems for detecting drugs and autoantibodies against TNF
PH12013502230A1 (en) Multispecific antibodies
NZ594315A (en) Antibody molecules having specificity for human ox40
MX2021015309A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
MX2007010349A (es) Composiciones y metodos para clasificar muestras biologicas.
HK1204994A1 (en) Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
JO2976B1 (en) Axentomodulin polypeptide
WO2009002380A3 (en) Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
MY159553A (en) Detection and treatment of pancreatic, ovarian and other cancers
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX2010005397A (es) Anticuerpo monoclonal capaz de unirse a anexelekto, y uso del mismo.
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
WO2008097439A3 (en) Anti-autoimmune antibodies for treatment of pemphigus
WO2010078945A3 (en) Cancer treatment
MX2010004615A (es) Anticuerpos monoclonales contra proteina c. activada e inactivada.
IN2012DN03338A (es)
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
NZ583894A (en) Antibodies that bind to a non atp binding p2x7 receptor
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
UA99292C2 (uk) Антитіло, яке специфічно зв'язується з нейропіліном-2в (nrp2b)

Legal Events

Date Code Title Description
FG Grant or registration